The benefits of immunotherapy and the impact of available therapies for metastatic melanoma on the clinical outcome of patients in the Unified Health System (SUS). RSD [Internet]. 2025 May 14 [cited 2025 Jun. 28];14(5):e5014548809. Available from: https://ojs34.rsdjournal.org/index.php/rsd/article/view/48809